September 26, 2011 09:08 ET

Generic Drugs Market to Reach $358 Billion by 2016

ROCKVILLE, MD--(Marketwire - Sep 26, 2011) - has announced the addition of the new market intelligence report "Generic Drugs: The Global Market" to their collection of Generics Drugs market research. For more information, visit

This is a time of growth and change for the generic pharmaceuticals sector. Major aspects that combine to create an opportunity for an up-to-date market analysis include the following:

  • The demand for generics is increasing steadily because of pressure to control healthcare costs. At the same time, fierce price competition in this area has created difficulties for some companies because of slashed profit margins. The main result has been a wave of merger and acquisition (M&A) activity, and the rise of "supergenerics," offering added value as well as low prices. Not all traditional companies are positioned to exploit this trend.
  • A major growth driver for the generics sector is the fact that several blockbuster pharmaceutical brands are coming off-patent and are therefore open to generic competition -- the phenomenon widely known as the "patent cliff." But the originator companies are deploying formidable strategies to protect their franchises, including marketing their own branded generics.
  • With first-generation biopharmaceutical products reaching the end of their patent lives, a whole new market field -- biogenerics or biosimilars -- is opening up for those generics companies capable of (or prepared to buy-into) the technological expertise required.
  • The international landscape is changing for generics as for all pharmaceuticals. China, India, Russia, Mexico, and Brazil are among the rising markets for generic activity.

The report examines strategies employed by companies specializing in generics to meet the challenges of this highly competitive market, while also summarizing strategies employed by "originator" companies to forestall generic competition.

The global generics market is estimated at about $225 billion in 2011. By 2016, it is expected that the value of the total global generics sector will have risen to $358 billion, representing more than 18% of all pharmaceuticals, a projected compound annual growth rate (CAGR) of 9.7% between 2011 and 2016.

The North American market is estimated to reach nearly $73 billion in 2011 and is expected to increase at a 7.9% compound annual growth rate to reach nearly $107 billion in 2016.

Emerging market represents the second largest market category for generic drugs with the expected sale of $57 billion in 2011. This should reach nearly $115 billion in 2016, for a CAGR of 15.1%.

For more information, visit

About is the leading provider of global market intelligence products and services. With over 300,000 research reports from more than 700 top consulting and advisory firms, offers instant online access to the world's most extensive database of expert insights on global industries, companies, products, and trends. For more information, call Veronica Franco at 240-747-3016 or visit

Contact Information

  • Contact:
    Veronica Franco
    Email Contact